Sponsored by:
The AI Revolution in Multivigilance
During that whole process from clinical trials through postmarketing surveillance, companies carry out multivigilance – the monitoring and reporting of safety risks in new and existing life science products such as drugs, vaccines, medical devices, and combination products.
During that whole process from clinical trials through postmarketing surveillance, companies carry out multivigilance – the monitoring and reporting of safety risks in new and existing life science products such as drugs, vaccines, medical devices, and combination products.
Given the enormous resources devoted to developing new medicinal products while ensuring the well-being of patients, managing the exceedingly complex responsibility of multivigilance has become a crucial challenge for every company, from single-drug biotechs to global market leaders.
But just as new technologies are helping to create innovative new medicines, they’re also poised to revolutionize safety. In particular, artificial intelligence (AI) has the potential to replace manual processes and allow safety organizations to effectively handle the huge amount of data (and noise) they deal with every day.
Read our business brief to learn more.
About Oracle Health Sciences
As a leader in Life Sciences cloud technology, Oracle Health Sciences’ Clinical One and Safety One are trusted globally by professionals in both large and emerging companies engaged in clinical research and pharmacovigilance. With over 20 years’ experience, Oracle Health Sciences is committed to supporting clinical development, delivering innovation to accelerate advancements, and empowering the Life Sciences industry to improve patient outcomes. Oracle Health Sciences. For life.
